Day 3 - Thursday, November 20, 2025Thursday, 20 November 2025 - ET (Eastern Time, GMT-05:00)

Potential Medicaid budget reductions could significantly impact patient affordability and manufacturer assistance programs. This session will examine state-specific Medicaid changes, federal policy updates and strategies that manufacturers can employ to mitigate the effects on reimbursement and patient access.

As PBMs continue deploying accumulators, maximizers and alternative funding programs to drive cost savings, the ripple effects on patients, manufacturers and healthcare ecosystems are undeniable. Hear from a patient directly on how these cost sharing programs have impacted their healthcare journey.

With PBM revenue models shifting and legislative reform on the table, market access and copay teams must prepare for new contracting hurdles, formulary access restrictions and changing cost-sharing dynamics. As PBMs move away from rebates toward fee-based structures, manufacturers will see a ripple effect in copay design, accumulators/maximizers and patient affordability strategies.

• Learn how PBM strategies impact manufacturer copay programs and how to adjust for higher patient cost-sharing
• Understand formulary placement shifts and what to expect in payer negotiations.
• Legislative updates – will PBM reform materialize and how should manufacturers prepare?

As precision medicine and biomarker-driven therapies expand, seamless collaboration between manufacturers and diagnostic companies is more critical than ever. Effective partnerships can accelerate therapy adoption, streamline patient identification and enhance market access strategies. This session explores best practices for aligning commercialization efforts, navigating reimbursement hurdles and optimizing patient access through diagnostics.